eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
6/2012
vol. 50
 
Share:
Share:
more
 
 
abstract:
Original paper

Increased production of a proliferation-inducing ligand (APRIL) by the peripheral blood mononuclear cells predicts worse prognosis in patients with systemic sclerosis

Marek Bielecki
,
Krzysztof Kowal
,
Pawel Bernatowicz
,
Lech Chyczewski
,
Otylia Kowal-Bielecka

Reumatologia 2012; 50, 6: 461-471
Online publish date: 2012/12/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Objectives: A proliferation-inducing ligand (APRIL) plays a crucial role in survival of the peripheral B cells, and may contribute to the pathogenesis of systemic sclerosis (SSc) through upregulation of autoantibody production and maintenance of the autoimmune phenomenon. It has recently been shown that peripheral blood mononuclear cells (PBMC) from patients with SSc release significantly greater amounts of APRIL as compared with healthy controls (HC).

Aim of the study: To better understand the role of APRIL in the development of SSc we aimed to investigate the relationships between production of APRIL by PBMC and clinical outcome in patients with SSc.

Material and methods: Concentration of APRIL was measured in PBMC supernatants from 22 SSc patients and 17 healthy subjects using commercially available ELISA kits. SSc patients were subsequently followed for at least three years or until death, whichever happened earlier. Disease progression was defined as death due to SSc-related organ complication, development of a new or progression of pre-existing SSc-related organ involvement.

Results: Concentration of APRIL was significantly greater in supernatants of PBMC from SSc (1097 ±240 pg/ml/105) as compared with HC (851 ±171 pg/ml/105, p < 0.05). In SSc patients APRIL levels correlated with the severity of skin and lung involvement. PBMC from 7 patients who experienced progression of the disease released significantly greater amounts of APRIL (1326 ±105 pg/ml/105 cells) as compared with those SSc patients with stable disease (991 ±208 pg/ml/105 cells, p < 0.05) and HC. In regression analysis concentration of APRIL was independently associated with disease outcome (β coeff = –0.94, p = 0.0009).

Conclusions: We show for the first time that increased release of APRIL by PBMC is associated with worse disease outcome in SSc. Further studies are needed to investigate whether targeting APRIL might represent a new therapeutic possibility for treatment of SSc patients.
keywords:

systemic sclerosis, scleroderma, APRIL, pathogenesis, biomarker



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe